SulAmérica and Rede D’Or São Luiz have announced a combination
SulAmérica (B3:SULA11), a leading insurance company in Brazil, has announced a combination with Rede D’Or São Luiz S.A. (B3:RDOR3), the largest Brazilian hospital network. The companies had a combined market value of approximately US$21 billion on 18 February 2022.
SulAmérica is one of the largest insurance companies in Brazil and operates in the health and dental insurance, life and pension plans, and asset management sectors. The company was founded in 1895 and is headquartered in Rio de Janeiro, Brazil.
Rede D’Or is the largest integrated healthcare network in Brazil, operating in the health sector, with an extensive network of private hospitals.
One of Oaklins’ teams in Brazil acted as the sole financial advisor to SulAmérica on its combination with Rede D’Or São Luiz S.A. The transaction will be submitted for approvals at shareholders’ meetings of both companies and to relevant regulatory agencies. Once the closing date is defined the companies will inform the market.
Contáctese con el equipo de la transacción
Transacciones relacionadas
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Aprenda másbioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
Aprenda másBanook, backed by Motion Equity, has acquired Fluidda
Banook Group has acquired Fluidda NV, marking a strategic expansion into advanced in-silico trials and respiratory disease modeling. Combining Banook’s expertise in cardiac safety and clinical data services with Fluidda’s AI-driven respiratory analytics creates a powerful, integrated platform. This deal strengthens Banook’s position in the contract research organization (CRO) sector, offering pharmaceutical clients broader, technology-enabled solutions to drive drug development and reduce costs.
Aprenda más